Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study: Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1) zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1)
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Reference: Nivolumab plus cabozantinib in first-line treatment for advanced renal cell carcinoma
Study: Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/day (N:323) or sunitinib 50 mg/day,
New Indication: Cabozantinib Plus Nivolumab in non–Clear-Cell RCC
Study: Single-arm, phase 2 trial Non-clear cell RCC with 0-1 prior systemic therapies (n=47) Cabozantinib 40 mg once daily + nivolumab 240 mg/2 weeks or 480 mg/4 weeks Efficacy: Median
New Drug: Cabozantinib for differentiated thyroid cancer
Study: Double-blind, randomized Phase III trial (COSMIC-311) RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib Cabozantinib 60 mg daily vs. placebo Efficacy: ORR: 18% vs. 0% Median PFS: